Revolution Medicines (RVMD) Net Cash Flow (2019 - 2026)

Revolution Medicines' Net Cash Flow history runs 8 years deep, the most recent figure standing at $57.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 127.3% year-over-year to $57.2 million; the TTM figure through Mar 2026 stood at $108.5 million (up 137.05% YoY), while the FY2025 annual figure was -$158.2 million, down 3.77% from the prior year.
• Net Cash Flow for Q1 2026 stood at $57.2 million, down from $166.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $342.6 million in Q4 2024, with the low at -$407.7 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$10.8 million (2022), against an average of $19.7 million.
• Peak annual rise in Net Cash Flow reached 2554.39% in 2023, while the deepest fall reached 667.35% in 2023.
• Revolution Medicines' Net Cash Flow stood at -$17.5 million in 2022, then soared by 2030.45% to $338.4 million in 2023, then gained by 1.25% to $342.6 million in 2024, then tumbled by 51.46% to $166.3 million in 2025, then sank by 65.61% to $57.2 million in 2026.
• Business Quant data shows RVMD's Net Cash Flow at $57.2 million in Q1 2026, $166.3 million in Q4 2025, and -$184.1 million in Q3 2025.